Glossary
Clinical Trial Phase
Stage of human testing for a compound
Clinical trials are organized into sequential phases that answer different questions. Phase 1 studies focus on safety and dosing in a small number of people. Phase 2 and Phase 3 studies test whether the compound produces the intended effect in larger groups and compare it with other options. Later phases gather more information on safety and benefit before possible regulatory review.
Used in 16 research peptides
- MetabolicAOD-9604Modified HGH fragment 176-191 analog targeted at fat loss without GH side effects.
- MetabolicTesofensineTriple monoamine reuptake inhibitor with strong weight-loss data; not FDA-approved.
- MetabolicCagrilintideAmylin analog co-developed with semaglutide as 'CagriSema' for next-gen weight loss.
- PerformanceAnamorelinOral ghrelin-receptor agonist developed for cancer cachexia; approved in Japan as Adlumiz.
- PerformanceCapromorelinOral non-peptide ghrelin-receptor agonist; FDA-approved as a veterinary appetite stimulant.
- MetabolicSurvodutideInvestigational GLP-1 / glucagon dual agonist from Boehringer Ingelheim and Zealand Pharma.
- MetabolicMazdutideGLP-1 / glucagon dual agonist (Innovent / Eli Lilly) submitted in China for obesity 2024.
- MetabolicOrforglipronFirst oral non-peptide GLP-1 receptor agonist (Eli Lilly); Phase 3 obesity program.
- RecoveryLarazotide AcetateTight-junction regulator developed for celiac disease; reduces intestinal permeability.
- OtherIndolicidinTryptophan-rich bovine cathelicidin; broad-spectrum antimicrobial peptide.
- OtherMagainin 2Frog-skin-derived antimicrobial peptide; parent of the pexiganan topical antibiotic.
- MetabolicTesofensine + Metoprolol (Tesomet)Tesofensine paired with metoprolol (Tesomet) to control HR while preserving weight loss.
- MetabolicRetatrutide + Cagrilintide StackInvestigational community stack pairing a triple incretin agonist with a long-acting amylin analog.
- MetabolicCagriSema (Cagrilintide + Semaglutide)Investigational once-weekly fixed combination of the amylin analog cagrilintide and the GLP-1 agonist semaglutide, studied in the Phase 3 REDEFINE program for weight management.
- RecoveryARA-290 (Cibinetide)Investigational 11-amino-acid peptide derived from the helix-B region of erythropoietin that activates the innate repair receptor without stimulating red-blood-cell production; studied for small-fiber neuropathy.
- MetabolicAdipotide (FTPP)An investigational proapoptotic peptidomimetic that targets the blood supply of white fat; it produced weight loss in obese primates but caused reversible kidney effects, and human data are limited to a single early-phase safety study.
See also
Educational use only
This calculator is provided for research and educational purposes. Outputs are derived from the values you enter. Always verify your math and consult a licensed physician before acting on any result.